The CorMedix Inc. (CRMD) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, offering a detailed view of its financial condition, governance, and material events. CorMedix is a Nasdaq Global Market–listed biopharmaceutical company focused on therapeutic products for life-threatening conditions and diseases, including DefenCath for catheter-related bloodstream infection prevention and a portfolio of anti-infective and hospital products acquired through Melinta Therapeutics LLC.
Current reports on Form 8-K document significant developments such as the completion of the Melinta acquisition, the related contingent payment and registration rights agreements, the issuance of convertible senior notes, equity offerings, and preliminary or final quarterly results. For example, a Form 8-K filed on November 12, 2025 furnishes third-quarter 2025 financial results and guidance updates, while earlier 8-Ks describe the Melinta transaction terms and the convertible notes offering used in part to fund the deal.
Proxy statements on Schedule 14A provide insight into CorMedix’s corporate governance and capital structure decisions. A definitive proxy statement filed in October 2025 outlines proposals for a special meeting, including amendments to the company’s stock incentive plan, ratification of certificate of designation amendments, and changes to its certificate of incorporation affecting preferred stock voting rights.
Investors can also use this page to access periodic reports referenced in the company’s proxy and 8-K filings, which contain audited financial statements, risk factors, and management’s discussion and analysis. These filings explain how CorMedix reports revenue from DefenCath and the Melinta portfolio, records goodwill and intangible assets, and accounts for items such as deferred tax assets and non-GAAP measures like adjusted EBITDA.
In addition, insider and capital markets–related filings are available, including disclosures about equity offerings, convertible notes, and voting results from annual and special meetings. Stock Titan’s interface pairs these documents with AI-powered summaries that highlight key points from lengthy 10-K, 10-Q, 8-K, and proxy materials, helping users quickly understand transaction terms, clinical program disclosures, and changes in guidance without reading every page.
CorMedix Inc. (CRMD) is asking stockholders to approve nine proposals at its June 23, 2026 virtual annual meeting while highlighting a strong 2025. The company reported $311.7 million in 2025 revenue, including $258.8 million from DefenCath and $52.9 million from the legacy Melinta portfolio, and turned a prior-year loss into $163.0 million in net income, or $2.04 per diluted share.
Management emphasizes the 2025 acquisition of Melinta Therapeutics, which added a diversified hospital-focused portfolio including MINOCIN, REZZAYO, VABOMERE, ORABACTIV, BAXDELA, KIMYRSA and TOPROL‑XL, and expanded the commercial footprint ahead of anticipated reimbursement changes for DefenCath in 2026. Stockholders are asked to elect seven directors, approve say‑on‑pay and auditor ratification, and vote on multiple governance and charter changes.
Key governance items include ratifying historical amendments to preferred stock certificates of designation, adopting technical charter clean‑ups, establishing class‑based voting so only affected preferred holders vote on amendments solely impacting their series, designating Delaware and federal courts as exclusive forums for certain claims, and expanding officer exculpation consistent with recent Delaware law to aid recruitment and retention. An adjournment proposal would allow extra time to gather votes on select charter and ratification items.
CorMedix Therapeutics furnished an update on its Phase III ReSPECT trial of REZZAYO (rezafungin) in adults undergoing allogeneic stem cell transplantation. The study met its primary endpoint, showing non-inferiority in fungal-free survival at Day 90, with 60.7% fungal-free survival for rezafungin versus 59.0% for a standard antimicrobial regimen. Safety was comparable, with fewer toxicity-related discontinuations and a favorable profile for drug–drug interactions. CorMedix estimates a potential U.S. prophylaxis market opportunity for REZZAYO exceeding $2 billion and plans a pre-NDA meeting followed by an sNDA submission in 2H26 to seek an expanded indication.
CorMedix Inc. files a definitive proxy statement for its 2026 Annual Meeting and highlights 2025 operational results, the August 2025 acquisition of Melinta Therapeutics LLC, and several charter and governance proposals for stockholder approval.
Management reports $311.7 million total 2025 revenue, including $258.8 million in DefenCath net sales and $52.9 million from the partial-year Melinta portfolio, and $163.0 million net income ($2.04 per diluted share). The virtual Annual Meeting is scheduled for June 23, 2026 with record date April 24, 2026. Key proposals include ratification of certain preferred-stock certificate amendments, charter technical updates, a class-voting change, exclusive-forum designation, officer liability updates, director elections, say-on-pay, auditor ratification and an adjournment proposal.
CorMedix Inc: The Vanguard Group filed an amendment to its Schedule 13G reporting that, after an internal realignment, certain Vanguard subsidiaries will report holdings separately and The Vanguard Group now reports 0 shares and 0% ownership of CorMedix common stock as of the amendment. The filing explains the disaggregation is in accordance with SEC Release No. 34-39538 and is signed by Vanguard's Head of Global Fund Administration on 03/26/2026.
CorMedix Inc. furnished an updated investor presentation and reaffirmed its prior guidance that full-year 2027 DefenCath sales are estimated at $100–$140 million, clarifying an inadvertent reference to $100–$125 million on a recent earnings call. The presentation outlines a broader growth plan, including 2026 revenue guidance of $300–$320 million and adjusted EBITDA of $100–$125 million, driven by DefenCath and a diversified anti-infective portfolio. Pro forma 2025 net revenue is shown at $401 million, with Q4 2025 DefenCath sales of $91 million and 79.1 million common shares outstanding as of December 31, 2025. CorMedix also highlights late-stage expansion opportunities for DefenCath in total parenteral nutrition and for REZZAYO in fungal prophylaxis, alongside a cash and short-term investment balance of $149 million.
CorMedix Inc. reports a transformational 2025, moving to net income of $163.1 million from a $17.9 million loss in 2024, while carrying an accumulated deficit of $176.6 million as of December 31, 2025.
Growth is led by DefenCath, its first-in-class antimicrobial catheter lock, launched across U.S. hemodialysis settings in 2024 and now the largest contributor to net sales. The August 2025 acquisition of Melinta Therapeutics adds six marketed hospital anti-infectives plus cardiovascular drug TOPROL-XL, creating a broader acute-care portfolio.
DefenCath benefits from Medicare NTAP and ESRD TDAPA, but reimbursement will reset as NTAP ends in November 2026 and TDAPA shifts to a post-TDAPA add-on in July 2026, which the company expects to pressure net pricing in late 2026. CorMedix is also investing in label expansion for DefenCath and REZZAYO and advancing BARDA-supported pediatric and biothreat programs while relying on third-party manufacturing and extensive intellectual property and exclusivity protections.
CorMedix Inc. reported a strong finish to 2025, with fourth-quarter net revenue of $128.6 million, including $91.2 million from DefenCath and $37.4 million from the newly acquired Melinta portfolio, up sharply from $31.2 million in the prior-year quarter.
For full-year 2025, total revenue rose to $311.7 million and pro forma revenue, assuming a full year of Melinta, reached $401.3 million. The company generated net income of $163.1 million, or $2.04 per diluted share, reversing a $17.9 million loss in 2024, and delivered adjusted EBITDA of $77.2 million in Q4 2025. Operating expenses roughly doubled as CorMedix absorbed Melinta and invested in DefenCath and late-stage studies, while cash, cash equivalents and short-term investments totaled $148.5 million as of December 31, 2025.
CorMedix Inc. insider filing shows a new equity award to its Chief Legal Officer. Beth Zelnick Kaufman received 36,006 shares of common stock on February 4, 2026 at a price of $0.00, following achievement of performance stock unit (PSU) goals for the first of three performance periods.
The PSUs were originally granted on January 2, 2025 and remain subject to additional time-based vesting conditions before fully vesting. After this award, she beneficially owns 269,108 shares of CorMedix common stock directly.
CorMedix Inc. Chief Operating Officer Elizabeth Hurlburt reported an equity-related award linked to performance stock units. On 02/04/2026, she acquired 36,006 shares of CorMedix common stock at a reported price of $0.00, increasing her beneficial ownership to 278,539 directly held shares.
The filing explains this reflects achievement of performance stock units granted on January 2, 2025, after the Compensation Committee determined that performance conditions for the first of three performance periods were met. These units remain subject to additional time-based vesting requirements for Hurlburt.